Okuda et al. developed the inhibitor PE859 (179), this curcumin derivative has IC50 values of 1.2 μM and 0.66 μM, respectively, to inhibit Aβ and tau aggregations, and improved in vivo pharmacokinetics and pharmacological efficacy, making it is more competitive as an AD drug candidate than curcumin [102]. The gene discussed is MAPT; the disease is Alzheimer disease.